Mar 16, 2026, 12:01 AMprnewswire.comKLYG
Kelyniam Global Reports 2025 Financial Results
Company announcementsFinancial reports
Strong Second-Half Momentum Drives 85% Net Loss Improvement; FDA Clearance Secured for Innovative Fusion™ Biomaterial Implant; Board Rejects Undervalued Acquisition Interest CANTON, Conn., March 16, 2026 /PRNewswire/ -- Kelyniam Global (OTC: KLYG), a leader in custom cranial implants, today announced its financial results for the year ended December 31, 2025.